Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dual Antiplatelet (DAPT) Therapy Clear all
Recruiting Phase 4 Interventional

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

NCT07025148
View directory record Official record
Conditions
Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 27, 2026, 7:28 AM EDT
Completed Phase 4 Interventional Results available

The Dual Antiplatelet Therapy Study (DAPT Study)

NCT00977938
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
25,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
178
States / cities
Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 27, 2026, 7:28 AM EDT
Completed Not applicable Interventional Results available

XIENCE 28 USA Study

NCT03815175
View directory record Official record
Conditions
Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions
XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 27, 2026, 7:28 AM EDT
Completed Phase 4 Interventional Results available

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

NCT02548650
View directory record Official record
Conditions
Myocardial Infarction, Diabetes Mellitus, Peripheral Arterial Disease
Interventions
Vorapaxar, Clopidogrel, Aspirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 27, 2026, 7:28 AM EDT
Recruiting Phase 4 Interventional

The Switching Antiplatelet-9 (SWAP-9) Study

NCT06588595
View directory record Official record
Conditions
Coronary Arterial Disease (CAD)
Interventions
Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 27, 2026, 7:28 AM EDT
Completed Phase 4 Interventional

Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel

NCT02567461
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Edoxaban 60 mg, Edoxaban 30 mg, Clopidogrel 75 mg, Aspirin 81 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 27, 2026, 7:28 AM EDT
Recruiting Phase 4 Interventional

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

NCT06691191
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 90 mg, Prasugrel 10 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 27, 2026, 7:28 AM EDT
Completed Phase 4 Interventional Results available

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

NCT04006288
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Prasugrel, ticagrelor, aspirin, rivaroxaban
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 27, 2026, 7:28 AM EDT
Recruiting No phase listed Observational

Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

NCT06223607
View directory record Official record
Conditions
Baseline Thrombocytopenia
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 27, 2026, 7:28 AM EDT
Completed Not applicable Interventional Results available

XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.

NCT03218787
View directory record Official record
Conditions
Coronary Artery Lesions
Interventions
XIENCE, DAPT
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
101
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 88 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 27, 2026, 7:28 AM EDT
Completed Phase 4 Interventional

Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)

NCT00963781
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Thrombosis
Interventions
Medtronic Endeavor Stent, Reduced duration (6 months) DAPT
Device · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 27, 2026, 7:28 AM EDT
Recruiting Phase 4 Interventional

Vascular Trial Associated Registry Pilot

NCT07076082
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Clopidogrel (Plavix) Pharmacogenetic Test Reagents
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
45 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Detroit, Michigan • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 27, 2026, 7:28 AM EDT
Recruiting Phase 4 Interventional

Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study

NCT06821191
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
clopidogrel 75 mg, Prasugrel 5 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 27, 2026, 7:28 AM EDT
Not listed Phase 4 Interventional Results available

CYPRESS - CYPHER for Evaluating Sustained Safety

NCT00954707
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel & Aspirin, Prasugrel & Aspirin, Placebo & Aspirin
Drug
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
2,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Sep 27, 2026, 7:28 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

NCT05681702
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
aspirin plus clopidogrel, prasugrel or ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 27, 2026, 7:28 AM EDT
Completed Phase 3 Interventional

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

NCT05754957
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Milvexian, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
14,194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
162
States / cities
Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 141 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 27, 2026, 7:28 AM EDT
Not listed No phase listed Observational

Comparison of the VerifyNow® Aspirin Test and PRUTest® Platelet Reactivity Tests With Investigational Reagent to Reagents Registered in Japan

NCT03615846
View directory record Official record
Conditions
Platelet Aggregation, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Accriva Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Jacksonville, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Sep 27, 2026, 7:28 AM EDT
Terminated Not applicable Interventional Results available

Dual Antiplatelet Therapy Adherence With Reminder App Usage

NCT05071027
View directory record Official record
Conditions
Aneurysm Cerebral (Unruptured)
Interventions
Endovascular Neurosurgery
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 27, 2026, 7:28 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034
View directory record Official record
Conditions
Ischemic Stroke; Ischemic Attack, Transient
Interventions
Milvexian, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years and older
Enrollment
12,523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
127
States / cities
Mesa, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 102 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 27, 2026, 7:28 AM EDT
Completed Phase 4 Interventional Results available

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

NCT01106534
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Drug · Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
144
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 27, 2026, 7:28 AM EDT
Recruiting Phase 3 Interventional

One-Month DAPT in CABG Patients

NCT05997693
View directory record Official record
Conditions
Chronic Coronary Disease
Interventions
Ticagrelor 90 MG, Low-dose aspirin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
3
States / cities
Englewood, New Jersey • Flushing, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 27, 2026, 7:28 AM EDT
Completed No phase listed Observational

The xDAPT External Validation Study

NCT06736626
View directory record Official record
Conditions
Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
Percutaneous coronary intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 27, 2026, 7:28 AM EDT
Completed No phase listed Observational

Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry

NCT02362659
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 27, 2026, 7:28 AM EDT
Not listed Not applicable Interventional

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

NCT02594501
View directory record Official record
Conditions
Angina, Stable, Angina, Unstable, Anticoagulants
Interventions
COBRA PzF, Drug Eluting Stent
Device
Lead sponsor
CeloNova BioSciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
22
States / cities
Newark, Delaware • Jacksonville, Florida • Melbourne, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2020 · Synced Sep 27, 2026, 7:28 AM EDT